Monographie - Oxaliplatin

Poslední aktualizace :
29/10/2024

Oxaliplatin

Cheminė sandara

Prekinis pavadinimas

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axiplatin	Vokietija
Bendaplatin	Vokietija
Bioezulen	Brazilija
Celdach	Peru
Crisapla	Čilė, Ekvadoras, Venesuela
Crisatinox	Turkija
Dabenzol	Argentina, Ekvadoras
Dacplat	Argentina
Eloxarin	Ekvadoras
Eloxatin	Austrija, Belgija, Brazilija, Čilė, Didžioji Britanija, Egiptas, Iranas, Ispanija, Italija, Jungtinės Amerikos Valstijos, Jungtiniai Arabų Emyratai, Kolumbija, Liuksemburgas, Malaizija, Meksikas, Naujojoje Zelandijoje, Norvegija, Peru, Portugalija, Rumunija, Švedija, Šveicarija, Tailandas, Turkija, Venesuela
Eloxatine	Marokas, Prancūzija, Šveicarija
Entia	Kolumbija, Meksikas
Euroxaliplatine	Vokietija
Glenoxal	Peru
Goxyral	Argentina, Ekvadoras
Kebir	Argentina, Peru
Linoxa	Turkija
Lisix	Čilė
Metaplatin	Argentina
Oliptino	Argentina
Onicol	Čilė, Peru
Oxalibbs	Brazilija
Oxaliplan	Vokietija
Riboxatin	Vokietija

Bibliografija : Oxaliplatin

	tipas	leidinys
1662	Žurnalas	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1950	Žurnalas	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
2207	Žurnalas	André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239	Žurnalas	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253	Žurnalas	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2258	Laboratorija	Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. Ebewe Pharma 2007
2259	Laboratorija	Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. Ebewe Pharma 2007
2321	Žurnalas	Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. Stability of Oxaliplatin Solution. Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791	Žurnalas	Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015 ; 479 : 23-27.
2883	Žurnalas	Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369	Laboratorija	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3413	Žurnalas	Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004 ; 21, 5: 891-894.
3602	Laboratorija	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3634	Laboratorija	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3670	Žurnalas	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3706	Žurnalas	Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. Farm Hosp 2014 ;38, 3:154-161
4004	Žurnalas	Krämer I, Sarakbi I, Thiesen J, Mainz. Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. Krankenhauspharmazie 2017 ;38,7:334?340.

Mentions Légales